XJSEAIP
Market cap569mUSD
Dec 20, Last price
6,502.00ZAR
1D
-0.90%
1Q
-3.66%
Jan 2017
34.76%
IPO
87.38%
Name
Adcock Ingram Holdings Ltd
Chart & Performance
Profile
Adcock Ingram Holdings Limited manufactures, markets, and distributes healthcare products in South Africa, the United States, Canada, the United Kingdom, rest of Europe, and internationally. It offers a portfolio of over-the-counter products, prescription medicines, and consumer products, as well as instrumentation and surgical products. The company also provides a range of pharmaceutical products, such as women's health, cannabidiol oil, antiretroviral, dermatology, central nervous system, respiratory, ophthalmology, generics, cardiovascular, pain, gastroenterology, energy supplements, colds and flu, personal care, feminine hygiene, digestive well-being, allergies, baby care, cough, food and nutrition supplements, vitamins, and minerals supplements. In addition, it manufactures and supplies hospital and critical care products, including intravenous solutions, renal dialysis systems, and blood collection products. The company serves private and public sectors. Adcock Ingram Holdings Limited was founded in 1890 and is headquartered in Midrand, South Africa.
Valuation
Title ZAR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
Income | ||||||||||
Revenues | 9,643,128 5.60% | 9,131,852 4.89% | 8,705,817 11.95% | |||||||
Cost of revenue | 7,478,970 | 6,859,844 | 6,541,445 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 2,164,158 | 2,272,008 | 2,164,372 | |||||||
NOPBT Margin | 22.44% | 24.88% | 24.86% | |||||||
Operating Taxes | 310,812 | 307,222 | 301,265 | |||||||
Tax Rate | 14.36% | 13.52% | 13.92% | |||||||
NOPAT | 1,853,346 | 1,964,786 | 1,863,107 | |||||||
Net income | 814,009 -9.39% | 898,410 12.25% | 800,345 21.73% | |||||||
Dividends | (379,022) | (375,368) | (313,811) | |||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (395,511) | (475,212) | (9,765) | |||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 42,460 | 45,062 | 27,717 | |||||||
Long-term debt | 518,620 | 595,381 | 647,765 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 12,527 | 13,081 | 14,079 | |||||||
Net debt | (204,954) | (142,521) | (224,070) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 943,828 | 381,752 | 657,333 | |||||||
CAPEX | (127,741) | (148,086) | (329,783) | |||||||
Cash from investing activities | (125,137) | (141,624) | (323,311) | |||||||
Cash from financing activities | (810,431) | (504,638) | (37,494) | |||||||
FCF | 1,736,312 | 3,468,912 | (11,209) | |||||||
Balance | ||||||||||
Cash | 89,417 | 91,540 | 345,485 | |||||||
Long term investments | 676,617 | 691,424 | 554,067 | |||||||
Excess cash | 283,878 | 326,371 | 464,261 | |||||||
Stockholders' equity | 5,944,665 | 5,592,497 | 4,989,929 | |||||||
Invested Capital | 5,421,965 | 5,338,120 | 5,091,449 | |||||||
ROIC | 34.45% | 37.68% | 37.81% | |||||||
ROCE | 36.89% | 39.09% | 38.04% | |||||||
EV | ||||||||||
Common stock shares outstanding | 154,633 | 163,754 | 164,770 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 2,364,772 | 2,470,042 | 2,357,029 | |||||||
EV/EBITDA | ||||||||||
Interest | 97,462 | 59,664 | 45,401 | |||||||
Interest/NOPBT | 4.50% | 2.63% | 2.10% |